Hodges Capital Management Inc. Buys 3,591 Shares of Johnson & Johnson $JNJ

Hodges Capital Management Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 18.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,026 shares of the company’s stock after purchasing an additional 3,591 shares during the quarter. Hodges Capital Management Inc.’s holdings in Johnson & Johnson were worth $5,848,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Carrera Capital Advisors boosted its position in shares of Johnson & Johnson by 2.3% during the 2nd quarter. Carrera Capital Advisors now owns 20,094 shares of the company’s stock worth $5,103,000 after purchasing an additional 443 shares in the last quarter. Fire Capital Management LLC increased its position in Johnson & Johnson by 42.1% in the 2nd quarter. Fire Capital Management LLC now owns 3,221 shares of the company’s stock valued at $818,000 after buying an additional 955 shares in the last quarter. Ranch Capital Advisors Inc. increased its position in Johnson & Johnson by 9.4% in the 2nd quarter. Ranch Capital Advisors Inc. now owns 17,434 shares of the company’s stock valued at $4,428,000 after buying an additional 1,494 shares in the last quarter. Phoenix Wealth Advisors raised its stake in Johnson & Johnson by 2.0% during the 2nd quarter. Phoenix Wealth Advisors now owns 17,090 shares of the company’s stock worth $4,340,000 after buying an additional 338 shares during the period. Finally, Sunpointe LLC boosted its holdings in Johnson & Johnson by 2.7% in the second quarter. Sunpointe LLC now owns 15,952 shares of the company’s stock worth $4,051,000 after acquiring an additional 422 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $270.69 on Friday. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $276.47. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $255.08 and a 200-day moving average price of $242.72. The company has a market cap of $652.34 billion, a PE ratio of 31.37, a price-to-earnings-growth ratio of 2.55 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research note on Monday, August 3rd. Argus set a $300.00 target price on Johnson & Johnson in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $268.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted 510(k) clearance for the MONARCH QUEST 3 robotic bronchoscopy update. The system adds artificial-intelligence-powered planning, navigation and imaging capabilities, strengthening J&J’s position in the expanding robotic-assisted medical-procedure market. Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
• Positive Sentiment: The European Commission approved TECVAYLI combined with daratumumab for relapsed or refractory multiple myeloma. The decision was supported by Phase 3 results showing statistically significant progression-free and overall-survival improvements versus standard treatments, potentially expanding sales of J&J’s oncology portfolio. European Commission approves Johnson & Johnson’s TECVAYLI plus daratumumab
• Positive Sentiment: Analysts continue to favor J&J as a dividend-focused healthcare investment, citing its diversified operations and pipeline strength. Recent quarterly results also showed adjusted earnings and revenue ahead of consensus, with revenue up 6.6% year over year and full-year 2026 earnings guidance maintained at $11.60–$11.75 per share. Merck vs. J&J: Which Healthcare Giant Should Investors Choose?
• Neutral Sentiment: J&J’s potential interest in Seaport Therapeutics highlights continued investor focus on neuroscience and business-development opportunities, but no transaction has been announced. Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
• Negative Sentiment: Patent-protection losses remain a longer-term risk for several established drugs, although new medicines and recent approvals could help offset declining legacy-product sales. Johnson & Johnson Just Sent Shareholders an Important Message About Its Future

Insider Activity

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 63,972 shares of company stock worth $16,245,605. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.